Aristides Capital’s VolitionRx Ltd VNRX Stock Holding History

Aristides Capital’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,153	Closed	-$109K	–	243
2019 Q4	$109K	Buy	+1,153	New	+$120K	0.08%	205

Other funds holding VNRX

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Aristides Capital's VNRX Position: Q1 2020 in Review

Aristides Capital sold out of VolitionRx Ltd (VNRX) in Q1 2020, closing a stake of 1,153 shares — an estimated $109K sold.

Aristides Capital first reported a position in VNRX in Q4 2019 and held it in 1 quarter. The position peaked at $109K in Q4 2019. 31 funds tracked by Wall St. Rank hold VNRX as of Q1 2020.

Aristides Capital reported no remaining VolitionRx Ltd position as of Q1 2020 after selling out during the quarter.
Aristides Capital sold 1,153 VolitionRx Ltd shares in Q1 2020, an estimated $109K.
Aristides Capital first reported a position in VolitionRx Ltd in Q4 2019 and held it in 1 quarter.
Aristides Capital's VolitionRx Ltd position peaked at $109K in Q4 2019.
31 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.